The short answer
Henry Meds is our top pick for switchers. Score 7.8 of 10. Flat $179 per month at every dose, month-to-month with online cancel, and a clinical model that accepts an existing dose without forcing you to re-titrate. The cheapest predictable path if you are exiting a program with rising prices or a multi-month lock-in.
The short version
Patients who switch GLP-1 programs are typically optimizing for one of three things: lower monthly cost at maintenance dose, an exit from a 6 or 12-month commitment they regret, or a clinician who understands their tolerance and dose history. Switchers don't need a fast intake. They need a program that accepts dose-history documentation, prescribes at the dose they're already on without a forced re-titration, and prices the long run rather than the first month.
What we considered
- Maintenance-dose monthly cost (the bill that lands every month, not the headline starter price)
- Accepts existing dose without forced re-titration
- No lock-in (so a bad switch doesn't cost you 6 months)
- Pharmacy partner stability and disclosed continuity plan
- Speed from intake to first refill (most switchers can't afford a gap)
Top pick: Henry Meds
Henry Meds's flat $179 per month, online cancel and willingness to continue an existing dose without forced re-titration make it the cleanest switching path for compounded GLP-1 patients who want lower cost and less lock-in.
Read the full Henry Meds review →
Why Henry Meds won this category
Henry Meds wins on the metric that matters most for a switcher: predictable maintenance-dose pricing with no commitment. The $179 monthly is flat across every dose tier, which means if you're switching from a program that priced your maintenance dose at $400 or $500 you cut the bill in half without changing molecule. Mochi is the closest competitor at $178 monthly; the $1 difference is rounding and either is a clean choice.
Henry's clinical model accepts existing dose history. If you're already on 1.7 mg semaglutide weekly, Henry's clinician will continue you at 1.7 mg rather than restart at 0.25 mg. That sounds like an obvious feature, but several programs in our chart treat every new patient as a new titration, which costs you 3 to 4 months of weight-loss progress while you re-climb the ladder. Verify this on the intake form before paying; the explicit question to ask is 'will you continue me at my current dose given my pharmacy fill history?'
The cancellation terms are clean. Month-to-month, online self-serve cancel, no prepay or non-refundable membership fee. If you switch to Henry and the pharmacy partner changes or supply is disrupted, you walk without a financial penalty. This matters in 2026 because compounded GLP-1 enforcement has tightened and the operating environment is fluid.
The trade-off, like Mochi, is the compounded medication path. Henry prescribes compounded semaglutide and tirzepatide from 503A pharmacies. If you're switching specifically because you want to move from compounded to branded, Henry is the wrong direction. For branded switchers, PlushCare or Form Health are the cleaner picks. For switchers staying on compounded but looking for lower monthly cost and no lock-in, Henry is the cleanest path.
Who this pick isn't for
Henry Meds is not the right pick if you're switching to escape compounded entirely. The Lilly lawsuits against compounded tirzepatide pharmacies through 2025 and the FDA's October 2024 semaglutide shortage resolution have made the regulatory exposure on compounded GLP-1s real. If you're switching specifically to brand Wegovy or Zepbound for regulatory clarity, look at Ro Body's $299 LillyDirect path or PlushCare's insurance-billed branded path.
Henry is also wrong if you're switching because your medical complexity outgrew the program you were on. Patients with new comorbidities (a recent T2D diagnosis, CV event, MASH workup) who need coordinated care across more than just the GLP-1 should switch to Knownwell or Form Health, not to another lightweight compounded program. The price is higher; the clinical depth justifies it.
And Henry isn't the right pick if your switch is driven by insurance coverage you just gained. If your new employer plan covers Wegovy or Zepbound with PA, you want PlushCare or Form Health, not cash-pay compounded. The PA paperwork takes 4 to 6 weeks but the monthly out-of-pocket lands at $25 to $50 rather than $179. Run the formulary check before assuming cash-pay is still your cheapest option.
Runner-up: Mochi Health
Mochi is roughly tied with Henry on price and lock-in terms, with a slight edge on clinical screening but a slight friction increase on intake. If Henry's pharmacy partner pool doesn't match your state, Mochi is the next call.
Read the full Mochi Health review →
Top 3 compared
| Program | Score | Starts from | Lock-in | Time to Rx |
|---|---|---|---|---|
| Henry Meds | 7.8 | $179/mo | Month-to-month | 2 days |
| Mochi Health | 7.6 | $178/mo | Month-to-month | 3 days |
| Medvi | 7.4 | $179/mo | Month-to-month | 2 days |
Other strong picks
Frequently asked
Can I switch mid-titration without restarting at 0.25 mg?
Yes, with documentation. Most programs that handle switchers (Henry, Mochi, Medvi) will continue you at your current dose if you provide pharmacy fill records or prior-prescriber letter showing dose history. Some programs (less commonly named ones) force a full re-titration regardless, which costs you 3 to 4 months of progress. Ask explicitly on the intake form before paying.
How long can I afford to be off medication during the switch?
Semaglutide half-life is about 7 days; tirzepatide is about 5 days. Steady-state appetite suppression typically persists 2 to 3 weeks past your last dose before you notice rebound hunger. Practical guidance: time your last fill at your old program to bridge a 7 to 10 day gap while the new program processes your intake. Henry and Mochi typically ship within 5 to 7 days of approval.
Will my new program write a different prescription than my old one?
Sometimes. Programs differ on whether they prescribe semaglutide or tirzepatide, branded or compounded, and at what dose increments. Henry and Mochi prescribe compounded semaglutide and tirzepatide. Ro Body's LillyDirect path is brand Zepbound only. PlushCare and Form Health will write whatever your insurance covers. Verify before paying.
Can I switch from compounded to brand?
Yes, and many switchers do this in 2026 as compounded enforcement tightens. The mechanics: a new program runs PA on branded Wegovy or Zepbound through your insurance, which takes 4 to 6 weeks. If approved, your copay drops to $25 to $50. If denied, you either appeal or you have a fallback compounded path. Our compounded-to-brand article covers the switch in detail.
What if my old program is still charging me?
Document the cancellation in writing (email confirmation, not phone-only). If the program continues to charge after a documented cancellation, file a chargeback with your card issuer. The Consumer Financial Protection Bureau's chargeback process is your tool here; programs with aggressive retention practices typically refund once a chargeback lands.
Will the new program need new labs?
Some do, some don't. Henry and Mochi typically don't require labs at switch. PlushCare and Form Health usually order labs for proper obesity-medicine workup. Knownwell always does labs as part of their primary-care model. If you have recent labs (within 6 months) most programs will accept those; ask before paying for new ones.
What's the cheapest path if I'm currently paying over $400 a month?
If you're on compounded today and paying $400-plus, switching to Henry, Mochi or Medvi at $178-$179 monthly cuts the bill more than half without changing molecule. If you're on branded retail cash-pay and paying $1,300 monthly, the cheapest move is to verify insurance coverage and route through PA via PlushCare or Form Health. If insurance won't cover it, switching to NovoCare ($199 to $499) or LillyDirect ($299) cuts brand cash-pay cost meaningfully.
Sources
- Wadden TA, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5)
- Rubino D, et al. STEP 4: weight maintenance after semaglutide discontinuation. JAMA 2021
- FDA: declared resolution of semaglutide shortage, October 2024
Related
